01828nas a2200289   4500000000100000008004100001260001200042653001200054653001100066653001200077653002200089653001500111100001500126700001300141700001400154700001800168700001200186700001300198700001200211700001500223245008600238856008100324300001100405490000700416520110100423022001401524       2021                            d  c01/202110aCXCL-1010aIFN-γ10aleprosy10amultidrug therapy10askin cells1 aFerreira H1 aMendes M1 aBarbosa M1 ade Oliveira E1 aSales A1 aMoraes M1 aSarno E1 aPinheiro R00aPotential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329534/pdf/fimmu-12-662307.pdf  a6623070 v123 a<p>The treatment of multibacillary cases of leprosy with multidrug therapy (MDT) comprises 12 doses of a combination of rifampicin, dapsone and clofazimine. Previous studies have described the immunological phenotypic pattern in skin lesions in multibacillary patients. Here, we evaluated the effect of MDT on skin cell phenotype and on the -specific immune response. An analysis of skin cell phenotype demonstrated a significant decrease in MRS1 (SR-A), CXCL10 (IP-10) and IFNG (IFN-γ) gene and protein expression after MDT release. Patients were randomized according to whether they experienced a reduction in bacillary load after MDT. A reduction in CXCL10 (IP-10) in sera was associated with the absence of a reduction in the bacillary load at release. Although IFN-γ production in response to  was not affected by MDT, CXCL10 (IP-10) levels in response to  increased in cells from patients who experienced a reduction in bacillary load after treatment. Together, our results suggest that CXCL10 (IP-10) may be a good marker for monitoring treatment efficacy in multibacillary patients.</p>  a1664-3224